Cormedix Inc
5 ballot items.
The Special Meeting will solicit stockholder approvals for five management proposals: Exchange Cap Removal, Incentive Plan Amendment increasing the plan shares by 4,312,000, Ratification of COD Amendments, Certificate of Incorporation Amendment to permit preferred stock voting on certain amendments, and Adjournment of the meeting if necessary to solicit additional proxies.
Follow how the vote landed and what changed on Cormedix Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot5
- 1
Approval of the Exchange Cap Removal
ManagementBoard: FORApprove removal of the Exchange Cap to allow issuance of shares under the Indenture, Merger Agreement with Melinta, and Contingent Payment Agreement beyond the current 19.99% cap, enabling necessary equity issuances in connection with the Merger and related arrangements.
- 2
Approval of the Incentive Plan Amendment Proposal
ManagementBoard: FORApprove an amendment to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan to increase the number of shares available for issuance by 4,312,000 (from 8,160,000 to 12,472,000).
- 3
Approval of the Ratification of the COD Amendments Proposal
ManagementBoard: FORRatify the COD Amendments (Series E and Series C-3 designations) and related amendments retroactive to their filing to eliminate uncertainty about their validity and effectiveness.
- 4
Approval of the Certificate of Incorporation Amendment Proposal
ManagementBoard: FORAmend the Certificate of Incorporation to allow holders of preferred stock to vote on amendments that relate solely to terms of one or more outstanding series of preferred stock, subject to law.
- 5
Approval of the Adjournment Proposal
ManagementBoard: FORApprove adjournment of the Special Meeting to a later date to solicit additional proxies if there are not sufficient votes on the foregoing proposals.
Nominees on the ballot
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 8.0% | 6,274,076 | $43M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0% | 3,129,656 | $21M |
| 3 | BlackRock, Inc. | 3.9% | 3,020,982 | $21M |
| 4 | BlackRock, Inc. | 2.8% | 2,230,138 | $15M |
| 5 | STATE STREET CORP | 2.8% | 2,191,843 | $15M |
| 6 | ROYCE ASSOCIATES LP | 2.4% | 1,887,532 | $13M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.0% | 1,560,261 | $11M |
| 8 | UBS Group AG | 1.9% | 1,505,443 | $10M |
| 9 | OBERWEIS ASSET MANAGEMENT INC/ | 1.5% | 1,211,115 | $8M |
| 10 | Alyeska Investment Group, L.P. | 1.1% | 850,000 | $6M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Cormedix Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Cormedix Inc 2025 special meeting?
- Cormedix Inc (CRMD) holds its 2025 special shareholder meeting on Monday, November 10, 2025.
- What is the record date for the Cormedix Inc 2025 meeting?
- The record date for the Cormedix Inc 2025 meeting is Tuesday, September 23, 2025. Shareholders of record on or before that date are eligible to vote.
- What proposals will shareholders vote on at the Cormedix Inc 2025 meeting?
- Shareholders will vote on 5 proposals at the Cormedix Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.